eo771 breast cancer cell line  (ATCC)

Journal: Advanced Science

Article Title: Mapping the Tissue‐of‐Origins of Mesenchymal Stromal Cells in Injury Repair

doi: 10.1002/advs.202509533

Figure Lengend Snippet: BM‐MSC‐derived myofibroblasts or CAFs were not detected in distal tissue fibrosis or tumors. A) Confocal imaging of kidney sections from normal and UUO‐induced renal fibrotic Pdgfra creER ;Sp7 dre ;R26 ZT1 mice treated with tamoxifen at 2 months old. Myofibroblasts were indicated with anti‐Col1 antibody staining. B) Confocal imaging of lung sections from normal and bleomycin‐induced pulmonary fibrotic Pdgfra creER ;Sp7 dre ;R26 ZT1 mice treated with tamoxifen at 2 months old. Myofibroblasts were indicated with anti‐Col1 antibody staining. C) Confocal imaging of liver sections from normal and CCl 4 ‐induced liver fibrotic Pdgfra creER ;Sp7 dre ;R26 ZT1 mice treated with tamoxifen at 2 months old. Myofibroblasts were indicated with anti‐Col1 antibody staining. D) Confocal imaging of liver sections from normal and DDC‐induced liver fibrotic Pdgfra creER ;Sp7 dre ;R26 ZT1 mice treated with tamoxifen at 2 months old. Myofibroblasts were indicated with anti‐Col1 antibody staining. E–H) Quantification of the percentages of DAPI + Col1 + myofibroblasts that were ZsGreen + and tdTomato + in renal fibrosis (E), pulmonary fibrosis (F), CCl 4 ‐induced liver fibrosis (G) and DDC‐induced liver fibrosis (H). n = 5 mice from 4 independent experiments. I) Confocal imaging of E0771‐induced subcutaneous tumors from Pdgfra creER ;Sp7 dre ;R26 ZT1 mice treated with tamoxifen at 2 months old. Cancer associated fibroblasts (CAFs) were indicated with anti‐Col1 antibody staining. J) Confocal imaging of normal colons and AOM/DSS‐induced colorectal cancer from Pdgfra creER ;Sp7 dre ;R26 ZT1 mice treated with tamoxifen at 2 months old. CAFs were indicated with anti‐Col1 antibody staining. K,L) Quantification of the percentages of DAPI + Col1 + CAFs that were ZsGreen + and tdTomato + in subcutaneous tumors (K) and colorectal cancer (L). n = 3 mice from 3 independent experiments.

Article Snippet: The E0771 mouse breast cancer cell line (CRL‐3461, RRID:CVCL_GR23) was obtained from the American Tissue Type Collection (ATCC) in 2018.

Techniques: Derivative Assay, Imaging, Staining

Journal: Nature Communications

Article Title: αTIGIT-IL2 achieves tumor regression by promoting tumor-infiltrating regulatory T cell fragility in mouse models

doi: 10.1038/s41467-025-64296-z

Figure Lengend Snippet: a Kaplan–Meier survival analysis of patients with TBNC based on the effector T reg score (mean expression of FOXP3 , CTLA4 , IFNG (inverted), TNF (inverted)). Data were acquired from The Cancer Genome Atlas (TCGA) and analyzed for significance by the log-rank test. b UMAP plot of individual datasets showing distinct T reg cell populations from responders or non-responders among patients with TBNC. c Gene Ontology enrichment analysis of scRNA-seq dataset in T reg cells for non-responders vs. responders post-ICB treatment. P values were computed with a one-sided hypergeometric test and adjusted for multiple comparisons using the Benjamini–Hochberg false discovery rate (FDR). d FOXP3 gene expression of T reg cells in the scRNA-seq dataset for non-responders vs. responders. e T reg functional score (mean expression of FOXP3, TIGIT, CTLA4, IL2RA, ENTPD1, ICOS, TNFRSF9, LAG3 ) expression level of T reg cells in the scRNA-seq dataset for non-responders vs. responders. f T reg functional score expression level of T reg cells in the scRNA-seq dataset from responder (left) and non-responder (right) for post-ICB treatment vs. pre-ICB treatment. g – i 6–8 weeks old female C57BL/6 J mice were inoculated with 2 × 10 5 EO771 cells. The tumor-bearing mice were administered the specified treatment intraperitoneally according to their respective groups ( n = 5 individual animals/group) on days 7, 10, and 13. Tumor volumes ( g , i ) were measured as indicated, and growth curves for each individual animal ( h ) are shown. j 33 weeks old female C57BL/6 J mice from αTIGIT-IL2 + αPD1 treated tumor free mice ( n = 2 individual animals) or 33w C57BL/6 J WT mice ( n = 2 individual animals) were inoculated with 5 × 10 5 EO771 cells. Tumor volume was measured as indicated. k , l 6–8 weeks old female Balb/c mice were inoculated with 1 × 10 5 4T1 cells. The tumor-bearing mice were administered the specified treatment intraperitoneally according to their respective groups ( n = 5 individual animals/group) on days 7, 10, and 13. Tumor volumes ( k ) were measured as indicated, and growth curves for each individual animal ( l ) are shown. Data represent mean ± SEM. The P value was determined by 2-tailed unpaired t -test ( d – f ) or 2-way ANOVA with Geisser-Greenhouse correction ( g , i , k ). Source data are provided as a Source Data file.

Article Snippet: The CTLL-2 cytotoxic T lymphocyte cell line (TIB-214), hybridoma cells PK136 (HB-191), 293 T cell line (CRL-3216), and EO771 mammary gland carcinoma cell line (CRL-3461) were purchased from the American Type Culture Collection (ATCC).

Techniques: Expressing, Gene Expression, Functional Assay

Journal: Science Advances

Article Title: Replacing cholesterol and PEGylated lipids with zwitterionic ionizable lipids in LNPs for spleen-specific mRNA translation

doi: 10.1126/sciadv.ady6460

Figure Lengend Snippet: ( A ) Schematic illustration of the timeline for B16F10-OVA tumor inoculation and vaccination (mRNA, 15 μg per mouse). ( B ) Photographs of the lungs. ( C ) H&E staining images of the lung tissues. Scale bars, 3000 μm. ( D ) Flow cytometry analysis of the population of CD8 + CD3 + T cells that bear T cell receptors binding to H2Kb OVA tetramer-SIINFEKL in the spleens. ( E ) Flow cytometry analysis of the population of IFN-γ + CD8 + CD3 + T cells in the spleens. ( F ) Flow cytometry analysis of the population of CD8 + CD3 + T cells that bear T cell receptors binding to H2Kb OVA tetramer-SIINFEKL in the blood. ( G ) Flow cytometry analysis of the population CD62L low CD44 high T cells (gated on CD8 + CD3 + cells) in the spleens. ( H ) Schematic illustration of the timeline for B16F10-OVA tumor inoculation, vaccination (mRNA, 15 μg per mouse), and tumor rechallenge. sc, subcutaneous. ( I ) Photographs of the tumors. ( J ) Individual tumor growth curves (PBS, gray; ThrCo LNP, steel blue). TFS, tumor-free survival. ( K ) Flow cytometry analysis of the population of CD8 + T cells (gated on CD3 + CD45 + cells) in B16F10-OVA tumors. ( L ) Flow cytometry analysis of the population of IFN-γ + CD8 + T cells (gated on CD3 + CD45 + cells) in B16F10-OVA tumors. ( M ) Flow cytometry analysis of the population of CD8 + T cells (gated on CD3 + CD45 + cells) in EO771 tumors. ( N ) Flow cytometry analysis of the population of IFN-γ + CD8 + T cells (gated on CD3 + CD45 + cells) in EO771 tumors. Data are presented as means ± SD from n biologically independent samples [(D) to (G), (I), and (K) to (N), n = 3]; [(J), n = 5]. Statistical significance was analyzed by one-way ANOVA with Tukey’s multiple comparisons test for [(D) to (G)] and t test for [(K) to (N)].

Article Snippet: DC2.4 cell line (SCC142) was purchased from Sigma-Aldrich, and B16F10-OVA (CRL-6475) and EO771 (CRL-3461) tumor cell lines were purchased from American Type Culture Collection.

Techniques: Staining, Flow Cytometry, Binding Assay